<div id=toc></div>

# Table of Contents

- [q-bio.GN](#q-bio.GN) [Total: 1]
- [cs.AI](#cs.AI) [Total: 1]
- [cs.LG](#cs.LG) [Total: 1]


<div id='q-bio.GN'></div>

# q-bio.GN [[Back]](#toc)

### [1] [Finding low-complexity DNA sequences with longdust](https://arxiv.org/abs/2509.07357)
*Heng Li,Brian Li*

Main category: q-bio.GN

TL;DR: Longdust是一个高效识别低复杂度DNA序列的新算法，通过统计建模k-mer分布来定义序列复杂度，在真实数据上表现优异


<details>
  <summary>Details</summary>
Motivation: 低复杂度DNA序列与变异密度增加和变异检测伪影相关，现有算法要么缺乏严格数学基础，要么在处理长上下文窗口时效率低下

Method: 通过统计建模k-mer计数分布来定义字符串复杂度，参数包括k-mer长度、上下文窗口大小和复杂度阈值

Result: 在真实数据上表现出高性能，与现有方法高度一致，能有效识别着丝粒卫星和中等长度基序的串联重复序列

Conclusion: Longdust提供了一个数学严谨且高效的低复杂度序列识别算法，解决了现有方法的局限性

Abstract: Motivation: Low-complexity (LC) DNA sequences are compositionally repetitive
sequences that are often associated with increased variant density and variant
calling artifacts. While algorithms for identifying LC sequences exist, they
either lack rigorous mathematical foundation or are inefficient with long
context windows.
  Results: Longdust is a new algorithm that efficiently identifies long LC
sequences including centromeric satellite and tandem repeats with moderately
long motifs. It defines string complexity by statistically modeling the k-mer
count distribution with the parameters: the k-mer length, the context window
size and a threshold on complexity. Longdust exhibits high performance on real
data and high consistency with existing methods.
  Availability and implementation: https://github.com/lh3/longdust

</details>


<div id='cs.AI'></div>

# cs.AI [[Back]](#toc)

### [2] [BDPM: A Machine Learning-Based Feature Extractor for Parkinson's Disease Classification via Gut Microbiota Analysis](https://arxiv.org/abs/2509.07723)
*Bo Yu,Zhixiu Hua,Bo Zhao*

Main category: cs.AI

TL;DR: 提出BDPM方法，结合随机森林和递归特征消除(RFRE)进行特征选择，开发混合分类模型分析肠道菌群数据，用于帕金森病早期预测


<details>
  <summary>Details</summary>
Motivation: 帕金森病误诊率高，现有深度学习模型多依赖单一分类器且忽略菌株间相关性和时间动态，需要更鲁棒的特征提取方法

Method: 收集39对帕金森患者与健康配偶的肠道菌群数据，开发RFRE特征选择框架整合生态学知识，设计混合分类模型捕捉微生物组时空模式

Result: 识别出差异丰度分类单元，建立了具有生物学可解释性的特征选择方法

Conclusion: BDPM方法为基于肠道菌群的帕金森病分类提供了更有效的特征提取方案，有望提高早期诊断准确性

Abstract: Background: Parkinson's disease remains a major neurodegenerative disorder
with high misdiagnosis rates, primarily due to reliance on clinical rating
scales. Recent studies have demonstrated a strong association between gut
microbiota and Parkinson's disease, suggesting that microbial composition may
serve as a promising biomarker. Although deep learning models based ongut
microbiota show potential for early prediction, most approaches rely on single
classifiers and often overlook inter-strain correlations or temporal dynamics.
Therefore, there is an urgent need for more robust feature extraction methods
tailored to microbiome data. Methods: We proposed BDPM (A Machine
Learning-Based Feature Extractor for Parkinson's Disease Classification via Gut
Microbiota Analysis). First, we collected gut microbiota profiles from 39
Parkinson's patients and their healthy spouses to identify differentially
abundant taxa. Second, we developed an innovative feature selection framework
named RFRE (Random Forest combined with Recursive Feature Elimination),
integrating ecological knowledge to enhance biological interpretability.
Finally, we designed a hybrid classification model to capture temporal and
spatial patterns in microbiome data.

</details>


<div id='cs.LG'></div>

# cs.LG [[Back]](#toc)

### [3] [Predicting effect of novel treatments using molecular pathways and real-world data](https://arxiv.org/abs/2509.07204)
*Adrien Couetoux,Thomas Devenyns,Lise Diagne,David Champagne,Pierre-Yves Mousset,Chris Anagnostopoulos*

Main category: cs.LG

TL;DR: 提出基于机器学习的模块化方法，利用药物-通路权重影响评分和患者数据预测未测试药物的疗效


<details>
  <summary>Details</summary>
Motivation: 在药物研发中，临床测试前预测药物疗效具有挑战性，需要开发能够利用真实世界数据和药物嵌入的预测框架

Method: 训练机器学习模型，使用药物-通路权重影响评分和患者数据（包括患者特征和临床结果），分析未测试药物在生物分子-蛋白质通路上的加权影响评分来预测疗效

Result: 在真实世界数据集上验证了方法的有效性，使用了两种不同的权重影响评分算法，并展示了在未见治疗上的泛化性能

Conclusion: 该方法提供了一个可迭代的初始框架，支持未来利用真实世界临床数据和药物嵌入来预测未测试药物效果的研究工作

Abstract: In pharmaceutical R&D, predicting the efficacy of a pharmaceutical in
treating a particular disease prior to clinical testing or any real-world use
has been challenging. In this paper, we propose a flexible and modular machine
learning-based approach for predicting the efficacy of an untested
pharmaceutical for treating a disease. We train a machine learning model using
sets of pharmaceutical-pathway weight impact scores and patient data, which can
include patient characteristics and observed clinical outcomes. The resulting
model then analyses weighted impact scores of an untested pharmaceutical across
human biological molecule-protein pathways to generate a predicted efficacy
value. We demonstrate how the method works on a real-world dataset with patient
treatments and outcomes, with two different weight impact score algorithms We
include methods for evaluating the generalisation performance on unseen
treatments, and to characterise conditions under which the approach can be
expected to be most predictive. We discuss specific ways in which our approach
can be iterated on, making it an initial framework to support future work on
predicting the effect of untested drugs, leveraging RWD clinical data and drug
embeddings.

</details>
